UPDATE: JPMorgan Starts IDEXX Laboratories (IDXX) at Overweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. S
10. COF

Go back to UPDATE: JPMorgan Starts IDEXX Laboratories (IDXX) at Overweight

UPDATE: IDEXX Labs (IDXX) Tops Q4 EPS by 62c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus

February 2, 2021 6:35 AM EST

(Updated - February 2, 2021 7:01 AM EST)

IDEXX Labs (NASDAQ: IDXX) reported Q4 EPS of $2.01, $0.62 better than the analyst estimate of $1.39. Revenue for the quarter came in at $720.94 million versus the consensus estimate of $680.03 million.

Achieves fourth quarter reported revenue growth of 19% and organic growth of 17%, driven by CAG Diagnostics recurring revenue reported growth of 23% and organic growth of 21%High revenue growth supported by sustained strong global trends in pet healthcareDelivers full year... More